a seismic shift in the treatment of children with cancer requires an equally radical change in our existing mindset
our project
CCRT RSII Initiative
XLII® Paraoncology®
Applied to the supremely complex field of cancer science and cancer medicine, XLII® has yielded Paraoncology®. Using this exceptional progression in medicine, the extensive resources of XLII® Medicine and Paraoncology® could now be applied to childhood cancer. The Childhood Cancer Research Trust’s funding of The Concorde Initiative proposition is directed towards ensuring the provision of health that cover off many different angles of each cancer’s critical dynamics, crucially not limited by the cancer type but focused on the specific characteristics of a given child’s cancer.
Phase I natural compound research and the current RSII Initiative are part of a multi-phase objective of developing effective natural compound programmes for children with cancer. Now that Kasper’s research data has been collated and extended, within the context of individual variance as this relates to both children and childhood cancers, the RSII Initiative seeks to identify the critical pathways that must be reflected in an overarching Template for XLII® TINCCs™ Paraoncology® for children.
We are currently raising money for the CCRT RSII Initiative which is focused on the scope of health in the context of cancer.
all available science can be triangulated against the molecular identity of the individual child and that child’s unique cancer.